DFX Intelligence
Quanta Therapeutics, Inc.
Venture-backed company · Stage unknown· South San Francisco, CA
As of · the latest observation of this company; each round carries its own date
Form D industry: Biotechnology
As of · the latest observation of this company; each round carries its own date
2 additional officers and directors
Every relationship, signal and contact on this record, with the source on each.
Includes 3 days of DFX Intelligence. Then $199/month unless canceled.
What matters now
- 2 investorsnamed
2 investors on record.
The investors already on the cap table shape who leads the next round.
- 5 directorsboard
5 directors on record from Form D filings and board-seat attributions.
The board is who decides on the next round and on a sale.
Drawing the relationship network…
Facts
- Year of incorporation
- unknown
- Revenue range (Form D)
- Decline to Disclosesec.gov
- Rounds on record
- 1
- Disclosed raised
- unknownsum of rounds with a disclosed amount only
- Named investors
- 2
Financing history
1 round
- May 10, 2023Form D equity offering · $76.2M (form d sold) · 17 investorsFact Form D · “Quanta Therapeutics, Inc. filed Form D/A: $76,192,272 sold of $89,098,282, Biotechnology”
Investors on record
2 edges
- Sofinnova Investments, Inc. board only, Maha Katabi (strongly supported) Inference sec.gov
- Vida Ventures Management board only, Rajul Jain (strongly supported) Inference sec.gov
Ownership and outcomes
How these are wordedA company a buyout or growth firm lists on its own site is “listed in the portfolio of”, never “acquired by”. A date prints only when a deal record gives one; otherwise the row says when DFX first saw it.none on record
Outcome stated by investors
No firm portfolio page lists this company, so no outcome is stated.
No later owner or exit on record: no private equity sponsor position and no acquisition, listing or IPO report names this company.
Credit relationships
How a loan is matchedA BDC reports its loans by borrower name. A position shows here only when the match passed a precision gate (a hand-labelled sample was 29 of 30 correct); the tier and confidence are printed on each row. Amounts are the lender’s reported position, never a round.none on record
No lender position matched to this company.
People
3 officers, 5 directors
- Cameron Pitt Executive Officer/Director sec.gov
- Derek Metzger Executive Officer sec.gov
- Perry Nisen Executive Officer/Director sec.gov
- Rajul Jain Director Inference
- Maria Fardis Director Fact
Show all 6 officers and directors
- Cameron Pitt Executive Officer/Director sec.gov
- Derek Metzger Executive Officer sec.gov
- Perry Nisen Executive Officer/Director sec.gov
- Rajul Jain Director Inference
- Maria Fardis Director Fact
- Maha Katabi Director Inference
Timeline
1 event
- Jun 24, 2026Quanta Therapeutics, Inc. filed Form D/A: $76,192,272 sold of $89,098,282, BiotechnologyForm D filed Fact Form D
Evidence
14 observations
Every observation on this company
- Entity type: Corporation Jun 24, 2026 Fact Form D
- Form D industry group: Biotechnology Jun 24, 2026 Fact Form D
- Amendment: true Jun 24, 2026 Fact Form D
- Revenue range (Form D): Decline to Disclose Jun 24, 2026 Fact Form D
- Incorporated: overFiveYears Jun 24, 2026 Fact Form D
- Jurisdiction: Delaware Jun 24, 2026 Fact Form D
- Amount sold (Form D): $76.2M Jun 24, 2026 Fact Form D
- Offering amount (Form D): $89.1M Jun 24, 2026 Fact Form D
- Exemptions: 06b Jun 24, 2026 Fact Form D
- First sale: 2023-05-10 Jun 24, 2026 Fact Form D
- Investors (Form D): 17 Jun 24, 2026 Fact Form D
- Minimum investment (Form D): 0 Jun 24, 2026 Fact Form D
- Securities offered: equity Jun 24, 2026 Fact Form D
- Office address: Jun 24, 2026 Fact Form D
Record history
1 dated event on the change ledger, latest event first
- Form D filed2026-06-24source on record
The ledger records every merge, rename and reclassification this record went through and the dated filings observed on it, so the identity on this page can be traced to the records it was built from. The ledger's own sentences name other records, so they show with the names.